547 related articles for article (PubMed ID: 24798001)
1. Genomic portrait of resectable hepatocellular carcinomas: implications of RB1 and FGF19 aberrations for patient stratification.
Ahn SM; Jang SJ; Shim JH; Kim D; Hong SM; Sung CO; Baek D; Haq F; Ansari AA; Lee SY; Chun SM; Choi S; Choi HJ; Kim J; Kim S; Hwang S; Lee YJ; Lee JE; Jung WR; Jang HY; Yang E; Sung WK; Lee NP; Mao M; Lee C; Zucman-Rossi J; Yu E; Lee HC; Kong G
Hepatology; 2014 Dec; 60(6):1972-82. PubMed ID: 24798001
[TBL] [Abstract][Full Text] [Related]
2. Alterations of RB1, p53 and Wnt pathways in hepatocellular carcinomas associated with hepatitis C, hepatitis B and alcoholic liver cirrhosis.
Edamoto Y; Hara A; Biernat W; Terracciano L; Cathomas G; Riehle HM; Matsuda M; Fujii H; Scoazec JY; Ohgaki H
Int J Cancer; 2003 Sep; 106(3):334-41. PubMed ID: 12845670
[TBL] [Abstract][Full Text] [Related]
3. Genetic Landscape and Biomarkers of Hepatocellular Carcinoma.
Zucman-Rossi J; Villanueva A; Nault JC; Llovet JM
Gastroenterology; 2015 Oct; 149(5):1226-1239.e4. PubMed ID: 26099527
[TBL] [Abstract][Full Text] [Related]
4. Klotho-beta and fibroblast growth factor 19 expression correlates with early recurrence of resectable hepatocellular carcinoma.
Lin ZZ; Hsu C; Jeng YM; Hu FC; Pan HW; Wu YM; Hsu HC; Hu MC; Cheng AL
Liver Int; 2019 Sep; 39(9):1682-1691. PubMed ID: 30698907
[TBL] [Abstract][Full Text] [Related]
5. Expression of fibroblast growth factor 19 is associated with recurrence and poor prognosis of hepatocellular carcinoma.
Hyeon J; Ahn S; Lee JJ; Song DH; Park CK
Dig Dis Sci; 2013 Jul; 58(7):1916-22. PubMed ID: 23456506
[TBL] [Abstract][Full Text] [Related]
6. Molecular cytogenetic evaluation of virus-associated and non-viral hepatocellular carcinoma: analysis of 26 carcinomas and 12 concurrent dysplasias.
Zondervan PE; Wink J; Alers JC; IJzermans JN; Schalm SW; de Man RA; van Dekken H
J Pathol; 2000 Oct; 192(2):207-15. PubMed ID: 11004697
[TBL] [Abstract][Full Text] [Related]
7. [Molecular genetic and epigenetic mechanisms of hepatocarcinogenesis].
Xue KX
Ai Zheng; 2005 Jun; 24(6):757-68. PubMed ID: 15946497
[TBL] [Abstract][Full Text] [Related]
8. Targeting FGF19 binding to its receptor system: a novel therapeutic approach for hepatocellular carcinoma.
Panera N; Ceccarelli S; Nobili V; Alisi A
Hepatology; 2015 Oct; 62(4):1324. PubMed ID: 25677789
[No Abstract] [Full Text] [Related]
9. Cell Culture System for Analysis of Genetic Heterogeneity Within Hepatocellular Carcinomas and Response to Pharmacologic Agents.
Gao Q; Wang ZC; Duan M; Lin YH; Zhou XY; Worthley DL; Wang XY; Niu G; Xia Y; Deng M; Liu LZ; Shi JY; Yang LX; Zhang S; Ding ZB; Zhou J; Liang CM; Cao Y; Xiong L; Xi R; Shi YY; Fan J
Gastroenterology; 2017 Jan; 152(1):232-242.e4. PubMed ID: 27639803
[TBL] [Abstract][Full Text] [Related]
10. Deregulation of RB1 expression by loss of imprinting in human hepatocellular carcinoma.
Anwar SL; Krech T; Hasemeier B; Schipper E; Schweitzer N; Vogel A; Kreipe H; Lehmann U
J Pathol; 2014 Aug; 233(4):392-401. PubMed ID: 24838394
[TBL] [Abstract][Full Text] [Related]
11. Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets.
Schulze K; Imbeaud S; Letouzé E; Alexandrov LB; Calderaro J; Rebouissou S; Couchy G; Meiller C; Shinde J; Soysouvanh F; Calatayud AL; Pinyol R; Pelletier L; Balabaud C; Laurent A; Blanc JF; Mazzaferro V; Calvo F; Villanueva A; Nault JC; Bioulac-Sage P; Stratton MR; Llovet JM; Zucman-Rossi J
Nat Genet; 2015 May; 47(5):505-511. PubMed ID: 25822088
[TBL] [Abstract][Full Text] [Related]
12. Detection of Novel Genomic Markers for Predicting Prognosis in Hepatocellular Carcinoma Patients by Integrative Analysis of Copy Number Aberrations and Gene Expression Profiles: Results from a Long-Term Follow-Up.
Cho HJ; Kim SS; Wang HJ; Kim BW; Cho H; Jung J; Cho SS; Kim JK; Lee JH; Kim YB; Yang MJ; Yoo BM; Lee KJ; Cho SW; Cheong JY
DNA Cell Biol; 2016 Feb; 35(2):71-80. PubMed ID: 26624274
[TBL] [Abstract][Full Text] [Related]
13. Genomic landscape of copy number aberrations enables the identification of oncogenic drivers in hepatocellular carcinoma.
Wang K; Lim HY; Shi S; Lee J; Deng S; Xie T; Zhu Z; Wang Y; Pocalyko D; Yang WJ; Rejto PA; Mao M; Park CK; Xu J
Hepatology; 2013 Aug; 58(2):706-17. PubMed ID: 23505090
[TBL] [Abstract][Full Text] [Related]
14. Variable Intra-Tumor Genomic Heterogeneity of Multiple Lesions in Patients With Hepatocellular Carcinoma.
Xue R; Li R; Guo H; Guo L; Su Z; Ni X; Qi L; Zhang T; Li Q; Zhang Z; Xie XS; Bai F; Zhang N
Gastroenterology; 2016 Apr; 150(4):998-1008. PubMed ID: 26752112
[TBL] [Abstract][Full Text] [Related]
15. AXIN1 mutations in hepatocellular carcinomas, and growth suppression in cancer cells by virus-mediated transfer of AXIN1.
Satoh S; Daigo Y; Furukawa Y; Kato T; Miwa N; Nishiwaki T; Kawasoe T; Ishiguro H; Fujita M; Tokino T; Sasaki Y; Imaoka S; Murata M; Shimano T; Yamaoka Y; Nakamura Y
Nat Genet; 2000 Mar; 24(3):245-50. PubMed ID: 10700176
[TBL] [Abstract][Full Text] [Related]
16. Integrated exome sequencing and microarray analyses detected genetic defects and underlying pathways of hepatocellular carcinoma.
Chong ML; Knight J; Peng G; Ji W; Chai H; Lu Y; Wu S; Li P; Hu Q
Cancer Genet; 2023 Aug; 276-277():30-35. PubMed ID: 37418972
[TBL] [Abstract][Full Text] [Related]
17. Target genes discovery through copy number alteration analysis in human hepatocellular carcinoma.
Gu DL; Chen YH; Shih JH; Lin CH; Jou YS; Chen CF
World J Gastroenterol; 2013 Dec; 19(47):8873-9. PubMed ID: 24379610
[TBL] [Abstract][Full Text] [Related]
18. Integrated analysis of somatic mutations and focal copy-number changes identifies key genes and pathways in hepatocellular carcinoma.
Guichard C; Amaddeo G; Imbeaud S; Ladeiro Y; Pelletier L; Maad IB; Calderaro J; Bioulac-Sage P; Letexier M; Degos F; Clément B; Balabaud C; Chevet E; Laurent A; Couchy G; Letouzé E; Calvo F; Zucman-Rossi J
Nat Genet; 2012 May; 44(6):694-8. PubMed ID: 22561517
[TBL] [Abstract][Full Text] [Related]
19. Mutations in TP53, CTNNB1 and PIK3CA genes in hepatocellular carcinoma associated with hepatitis B and hepatitis C virus infections.
Tornesello ML; Buonaguro L; Tatangelo F; Botti G; Izzo F; Buonaguro FM
Genomics; 2013 Aug; 102(2):74-83. PubMed ID: 23583669
[TBL] [Abstract][Full Text] [Related]
20. Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets.
Boyault S; Rickman DS; de Reyniès A; Balabaud C; Rebouissou S; Jeannot E; Hérault A; Saric J; Belghiti J; Franco D; Bioulac-Sage P; Laurent-Puig P; Zucman-Rossi J
Hepatology; 2007 Jan; 45(1):42-52. PubMed ID: 17187432
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
